title: Is the Antitumor Property of Trypanosoma cruzi Infection Mediated by Its Calreticulin?
abstract: Eight to 10 million people in 21 endemic countries are infected with Trypanosoma cruzi. However, only 30% of those infected develop symptoms of Chagas' disease, a chronic, neglected tropical disease worldwide. Similar to other pathogens, T. cruzi has evolved to resist the host immune response. Studies, performed 80 years ago in the Soviet Union, proposed that T. cruzi infects tumor cells with similar capacity to that displayed for target tissues such as cardiac, aortic, or digestive. An antagonistic relationship between T. cruzi infection and cancer development was also proposed, but the molecular mechanisms involved have remained largely unknown. Probably, a variety of T. cruzi molecules is involved. This review focuses on how T. cruzi calreticulin (TcCRT), exteriorized from the endoplasmic reticulum, targets the first classical complement component C1 and negatively regulates the classical complement activation cascade, promoting parasite infectivity. We propose that this C1-dependent TcCRT-mediated virulence is critical to explain, at least an important part, of the parasite capacity to inhibit tumor development. We will discuss how TcCRT, by directly interacting with venous and arterial endothelial cells, inhibits angiogenesis and tumor growth. Thus, these TcCRT functions not only illustrate T. cruzi interactions with the host immune defensive strategies, but also illustrate a possible co-evolutionary adaptation to privilege a prolonged interaction with its host.
authors.affiliation: Faculty of Veterinary Medicine and Livestock Sciences, University of Chile , Santiago , Chile.
authors.forename: Galia
authors.initials: G
authors.lastname: Ramírez-Toloza
authors.affiliation: Program of Immunology, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile , Santiago , Chile.
authors.forename: Paula
authors.initials: P
authors.lastname: Abello
authors.affiliation: Program of Immunology, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile , Santiago , Chile.
authors.forename: Arturo
authors.initials: A
authors.lastname: Ferreira
keywords: C1q; Trypanosoma cruzi; cC1qR; calreticulin; complement system; immune response; trypomastigotes; tumor growth